Is it true that giritinib has a 70% clearance rate for FLT3 gene mutations?

According to existing research and clinical trial data, Gilteritinib, as a drug for the treatment of FLT3 gene mutations, has a potentially high clearance rate. However, treatment effectiveness will still vary depending on individual patient differences and disease characteristics.

A clinical trial conducted in patients with relapsed or refractory acute myeloid leukemia showed that the treatment regimen of geritinib can achieve approximately70% clearance rate of FLT3 gene mutations. This means that after treatment with giritinib, approximately 70% of patients can observe a reduction or disappearance of FLT3 gene mutations. It should be noted that efficacy data may vary based on different studies and trial designs, and may also be affected by the selection of patient groups and disease conditions. Therefore, in actual treatment, the specific treatment effect still needs to be determined based on the doctor's evaluation and the patient's response.

The original drug of geritinib has been launched in China, but it has not yet been included in the medical insurance. The price of each box of 40mg*42 tablets may be more than 20,000 yuan. The price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. Generic drugs of giritinib are currently produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*84 tablets per box produced by a Laos pharmaceutical factory is more than 4,000 yuan (the price may fluctuate due to the exchange rate).